The big trouble for invasive fungal infection(IFI)is how to define the diagnosis.Delayed therapy is the main reason of the death in the IFI patients,which underlines the importance of empiric therapy.Both cost-effectiveness ratio and patients' particular status should be considered when choosing an antifungal drug.Amphotericin B,Itraconazole,voriconazole,caspofungin and micafungin are all recommended.But there are still plenty of questions unanswered about empiric therapy,for example,how to establish th therapy based on scientific evidence.

Arsenicals ; therapeutic use ; Humans ; Leukemia, Promyelocytic, Acute ; drug therapy ; Medicine, Chinese Traditional ; Oxides ; therapeutic use

Hematopoietic stem cell transplantation (HSCT) is an effective and sometimes the only curative therapy for patients with certain hematological diseases.HSCT has been practiced in China for approximately fifty years,and great improvements have been made within the past decade,especially in fields such as haploidentical HSCT system,strategies to overcome relapse and GVHD.This review will describe the current situation and provide a prospective of these novel characteristics of HSCT system in China.

China ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; diagnosis ; therapy ; Practice Guidelines as Topic

Hematopoietic stem cell transplantation (HSCT) is the only effective curative therapy for patients with certain hematological diseases. Haploidentical HSCT has been practiced worldwide for approximately twenty years. Significant improvements on this therapy were made in China within the past decade, with the novel non-in-vitro, T-cell-depleted haploidentical HSCT system. This review de-scribes the current situation and provides a prospective overview of these novel HSCT systems in China.

Imatinib mesylate,as the first generation Bcr-Abl tyrosine kinase inhibitor,has brought revolutionary treatment for Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML);it has been recommended as the first-line treatment for CML by NCCN Practice Guidelines in Oncology in 2008 and European LeukemiaNet(ELN) criteria.However,imatinib has three limitations:first,it is expensive and can not be stopped if efficancy to be maintained;Second,some 20%~30% of patients develope resistance to imatinib;and third,the CML patients can not be cured with imatinib.Taking into consideration of the situation in China,we recommend individual therapy using TKI,HSCT,interferon and cytotoxic drugs for CML patients in China.

The indications for patients with Myelodysplastic Syndrome (MDS) to receive allogeneic hematopoietic stem cell transplantation (Allo-HCT) are:intermediate risk-2 and high risk groups according to IPSS,and intermediate risk-1 group with poor karyotype,severe multilineage cytopenia or infusion-dependent.Constant follow-up and evaluation is important for therapeutic decision.Unrelated or related haploidentical donor could be an alternative in case of absence of identical sibling donor.Remission through chemotherapy before the transplantation is recommended in patients with advanced MDS who receive reduced-intensity conditioning.Demethylation drugs followed by Allo-HCT do not show additional transplantation-related toxicity,whose efficiency remains to be determined.

ObjectiveTo compare the sensitivity among three diagnostic criteria for multiple myeloma.MethodsA total of 220 patients with multiple myeloma were studied retrospectively to compare thesensitivity, aswellastheirclinicalmanifestations, cellmorphologyinbonemarrowand immunophenotype.Results (1) The sensitivity of domestic diagnostic criterion in 1975 was 79.1％ (174/220) and there were some drawbacks in type identify.The sensitivity of WHO diagnostic criterion in 2001 was 97.3％ (214/220) and the sensitivity of domestic diagnostic criteria in 2011 was 100％. (2) Immunoglobulin level in 12.7％ (28/220) patients was ＜ 30 g/L,plasma cells count in bone marrow in 13.6％ (30/220) was ＜ 10％ ; 2.7％ (6/220) patients had not met the standard in immunity globulin and bone marrow plasma cells count.(3) The immunophenotype was CD38 positive ( 100％ ),restricted light chain (kappa/lambda) and CD19 100％,CD138 (98.2％,216/220) negative.ConclusionsAmong the three diagnostic criteria,the highest was 2011 domestic diagnostic criteria.Comprehensive analysis include clinical manifestations,cell morphology,immunophenotype will contribute to the diagnosis for multiple myeloma.

The treatment for chronic myeloid leukemia is still a challenge,at present.Tyrosine kinase inhibitors can partially control chronic myeloid leukemia in blast crisis (CML-BC),but the effect is not durable.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only way that can cure CML-BC.This paper presents a review of the treatment before allo-HSCT for CML-BC,the selection of condition regimen,donor and hematopoietic stem cell,the monitoring of MRD post-transplant,the prophylaxis and intervention of relapse.

Objective To carry out the performance evaluation to insure security of inner canister during the design phase, which is the important thin component of the portable sterilizater. Methods The software Mechanica, one of the module of Pro/Engineer was implemented to the flexure analysis of the inner canister. Results The stabilization and strength of inner canister satisfied requirements of the design. Conclusion Not only the security of design data can be proved but the cost and cycle of design can be reduced by using the method of expansion simulation analysis at the same time of the design phase of the equipment.